Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2R01DA029910-06 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ukrainian Institute on Public Health Policy | OTHER |
| AFEW Kyrgyzstan | UNKNOWN |
| AFI - Act For Involvement | UNKNOWN |
| National Institute on Drug Abuse (NIDA) |
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy a Screening, Brief Intervention, and Referral to Treatment (SBIRT) program for linking opioid dependent individuals currently incarcerated or in probation in Moldova, Kyrgyzstan, and Ukraine to opioid substitution therapy in the community after release or during their probation period.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program | Experimental | There are two objectives to the Brief Intervention. First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SBIRT | Behavioral | First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder. In our BI, we will provide evidence-based information on Opioid Agonist Therapy (OAT) that is available to them in the community upon release or in the community. We will inform them of the risks and benefits of OAT and explain to them how OAT can be accessed in the community. OAT is provided at no cost to Ukrainian, Moldovan, and Kyrgyz citizens with opioid dependence. The BI will last approximately 20 minutes and time will be made available for them to ask questions. The BI will not be audio recorded. |
| Measure | Description | Time Frame |
|---|---|---|
| Enrollment on OAT | Total number of participants who enroll on OAT divided by the number of participants who underwent study procedures, per country. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| OAT Knowledge | Overall mean change in composite score of knowledge of OAT pre vs post intervention stratified by study groups (enrolled vs not en rolled on OAT) at the 6-month mark. | 6 month |
| OAT Attitudes |
Not provided
Inclusion Criteria:
18 years of age or older
Within 180 days of release or possible release (eligible for parole) to the community, but greater than 7 days to release to the community OR currently in probation.
FOR THOSE IN PRISON: Relocating to a location within 30 km (approximately 60-minute commute) of the referred Narcology center. Each participant will be asked the address he/she is planning to reside under that will be immediately checked on the map to determine the travel time. A participant then will be asked if he/she would be willing to travel the distance to a particular OAT site. If a person does not meet this inclusion criterion, he/she will be referred to a local harm reduction center.
Meets ICD-10 screening criteria for pre-incarceration opioid dependence
FOR THOSE IN PROBATION:
Living within 30 km of an OAT delivery site
Not having received OAT in the last 15 days.
Positive for OUD
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frederick L Altice, MD | Yale University | Principal Investigator |
| Natalya Shumskaya | AIDS Foundation East-West | Study Director |
| Nataliia Saishuk | Ukrainian Institute for Public Health Policy | Study Director |
| Svetlana Doltu | AFI - Act For Involvement | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AIDS Foundation East-West | Bishkek | Kyrgyzstan | ||||
| AFI - Act for Involvement |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Aug 7, 2025 | |
| Reset | Aug 25, 2025 |
Not provided
| NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
|
Overall mean change in composite score of attitudes towards OAT pre vs post intervention stratified by study groups (enrolled vs not en rolled on OAT) at the 6-month mark.
| 6 months |
| Interest in OAT | Overall mean change in composite score of interest in initiating OAT pre vs post intervention stratified by study groups (enrolled vs not en rolled on OAT) at the 6-month mark. | 6 months |
| OAT Difficulty | Overall mean change in composite score of difficulty in initiating OAT pre vs post intervention stratified by study groups (enrolled vs not en rolled on OAT) at the 6-month mark. | 6 months |
| OAT Importance | Overall mean change in composite score of importance of initiating OAT pre vs post intervention stratified by study groups (enrolled vs not en rolled on OAT) at the 6-month mark. | 6 months |
| Chisinau |
| Moldova |
| Ukrainian Institute for Public Health Policy | Kyiv | Ukraine |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Aug 7, 2025 | Aug 25, 2025 |
| ID | Term |
|---|---|
| D009293 | Opioid-Related Disorders |
| D015658 | HIV Infections |
| D014376 | Tuberculosis |
| D006526 | Hepatitis C |
| D006509 | Hepatitis B |
| D003863 | Depression |
| D013587 | Syphilis |
| ID | Term |
|---|---|
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D006525 | Hepatitis, Viral, Human |
| D018178 | Flaviviridae Infections |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D018347 | Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D014211 | Treponemal Infections |
| D013145 | Spirochaetales Infections |
| D016905 | Gram-Negative Bacterial Infections |
| D015231 | Sexually Transmitted Diseases, Bacterial |
Not provided
Not provided